After President Trump talked up leucovorin as a possible treatment for autism, demand for the FRAT blood test spiked https://t.co/KWixEVgvEV ...

All right, welcome back everybody. Luccoin is a generic drug derived from folic acid and currently approved for easing the side effects of chemotherapy in some patients. But after President Trump and HHS Secretary Robert F.Kennedy Jr. . announced a push to approve the drug for cerebral folate deficiency, that's a condition that often co-occurs with the ocism spectrum disorder that led the way for many new patients to seek out the medication. Joining us right now is an author of one study of luccoin conducte ...

The US Food and Drug Administration said it will approve the use of cancer drug leucovorin for a condition seen in some people with autism. Here's what to know https://t.co/BFOvL9Xe3e ...

Core Viewpoint - The heads of key health agencies are advocating for a focus on leucovorin, while Kennedy emphasizes the importance of raising awareness about the risks associated with acetaminophen [1] Group 1 - Key health agency leaders support prioritizing leucovorin in health discussions [1] - Kennedy feels a moral obligation to inform the public about acetaminophen risks [1]

Healthcare & Pharmaceutical Industry - Trump is promoting leucovorin as a possible autism treatment [1] - Medical professionals caution that leucovorin's effectiveness for autism may be exaggerated [1] - Further investigation is necessary to ascertain the true benefits of leucovorin for autism [1]

Healthcare Industry Focus - The Trump administration is promoting leucovorin as a possible autism treatment [1] - Medical professionals caution that leucovorin's advantages may be exaggerated and that further investigation is required [1]

What you need to know about leucovorin, the cancer drug the FDA will approve to treat autism. https://t.co/4xeuizxXVS ...

Group 1: Company Impact - Shares of Tylenol manufacturer Kenvue fell by 5.5% on the trading day following the announcement, marking a total decline of 17% in September due to the administration's potential link of the drug to autism [8] - Kenvue, which was spun off from Johnson & Johnson in 2023, stated that independent science shows no causal link between acetaminophen and autism, expressing concern over the health risks posed to expecting mothers by such claims [11] Group 2: Industry Context - The U.S. autism diagnosis rate has significantly increased, with the rate for 8-year-olds reaching 1 in 36 (2.77%) by 2020, up from 2.27% in 2018 and 0.66% in 2000, raising public concern [12] - Experts attribute the rise in autism diagnoses to improved screening methods and broader definitions of the condition, which have led to the identification of individuals with milder symptoms [14]

Core Viewpoint - The Trump administration has drawn an unproven link between acetaminophen use during pregnancy and autism, contradicting existing scientific literature that suggests no causal relationship [1][4][9] Group 1: Acetaminophen and Pregnancy - Acetaminophen, particularly in the form of Kenvue's Tylenol, is widely regarded as a safe option for pain and fever relief during pregnancy when used at recommended doses [2] - Kenvue has expressed strong disagreement with the administration's claims, emphasizing that independent scientific evidence supports the safety of acetaminophen and warns against the health risks posed to expecting mothers if they avoid the drug [3][4] Group 2: Risks of Untreated Conditions - Untreated fever and pain during pregnancy can lead to serious risks for both the mother and infant, including miscarriage, birth defects, and high blood pressure, as noted by the Society for Maternal-Fetal Medicine [4] Group 3: Leucovorin as a Treatment - The Trump administration has also highlighted leucovorin as a potential treatment for autism symptoms, with some early clinical trials indicating its effectiveness in improving symptoms in children with autism spectrum disorder [5] - The FDA announced approval for a version of leucovorin previously made by GSK, although there was a subsequent request to withdraw this notice [6] Group 4: Broader Context of Autism Research - Robert F. Kennedy Jr. has focused on autism within the Health and Human Services department, pledging to identify its causes and eliminate exposures, while also launching extensive research efforts involving numerous scientists [8] - The scientific consensus suggests that autism arises from a complex interplay of genetic and environmental factors, making it improbable that a single cause accounts for the rising rates of the disorder [9]

Core Viewpoint - Kenvue Inc. (KVUE), the parent company of Tylenol, is experiencing a decline in stock price due to concerns raised by the Trump administration linking Tylenol to autism risk, despite existing studies refuting this claim [2][5][6]. Company Overview - Kenvue was spun off from Johnson & Johnson in 2023 and is known for various household products, including Tylenol, Band-Aid, Listerine, and Zyrtec [3]. - Tylenol, containing acetaminophen, has been available over-the-counter in the U.S. since 1960 and is widely used for pain relief and fever reduction [4]. Industry Concerns - Federal health officials are expected to announce concerns regarding the use of acetaminophen by pregnant women, citing research suggesting a potential link to autism [5]. - The CDC reported that the diagnosis rate of autism in American 8-year-olds has increased from one in 150 in 2000 to one in 31 in 2022, highlighting a growing public health concern [8]. Response from Kenvue - Kenvue has stated that acetaminophen does not cause autism, aiming to clarify the safety of their product amidst rising concerns [8].